aRigen taps Taiho as Japan partner
This article was originally published in Scrip
Executive Summary
The private Japanese venture aRigen Pharmaceuticals has struck its first major out-licensing deal for an in-house molecule, awarding Taihothe Japanese rights to a novel therapy for the eradication of Helicobacter pylori.